Please wait while the transcript is being prepared...
Hello. My name is Mark Awad.
I'm the Clinical Director for
the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute,
and assistant professor at Harvard Medical School.
I'll be discussing updates on immunotherapy for treatment of lung cancer.
This is an outline of our topics for discussion today.
We'll be discussing the role of immunotherapy in non-small cell lung cancer,
both for stage four disease as well as unresectable stage three,
surgically resectable, non-small cell lung cancer.
We'll discuss a bit about some emerging data in small-cell lung cancer.
So to start, we'll talk about stage
four non-small cell lung cancer where the first approvals of immunotherapy occurred.
There have been a number of rapid developments in
immuno-oncology non-small cell lung cancer over the past few years.
Before 2015, the standard of care for non-small cell lung cancer was to
use first-line platinum doublet chemotherapy followed by a second line docetaxel.
Typically after that point,
patients would be referred for best supportive care.
Our previous standard second line therapy docetaxel
has a low response rate typically of around seven percent.
But this was the standard of care from the year early 2000s up until about 2015.
We first had the approvals of immunotherapy in the second line setting based on
several large phase three clinical trials comparing
PD-1 or PD-L1 inhibitors against docetaxel,
all of which showed an overall survival benefit over docetaxel.
These agents then became approved in the second line setting.
We'll review the data on these seminal trials
moving docetaxel more so now into the third line setting.